ZYVOX Drug Patent Profile

When do Zyvox patents expire, and what generic alternatives are available?

Zyvox is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in ZYVOX is linezolid. There are twenty-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the linezolid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyvox

A generic version of ZYVOX was approved as linezolid by HIKMA on June 3^rd, 2015.

Summary for ZYVOX

US Patents:	0
Applicants:	1
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZYVOX

Paragraph IV (Patent) Challenges for ZYVOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYVOX	Injection	linezolid	2 mg/mL, 100 mL bag	021131	1	2009-12-29
ZYVOX	Injection	linezolid	2 mg/mL, 300 mL bag	021131	1	2009-09-01
ZYVOX	Oral Suspension	linezolid	100 mg/5 mL	021132	1	2009-08-03
ZYVOX	Tablets	linezolid	600 mg	021130	1	2005-12-21

US Patents and Regulatory Information for ZYVOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ZYVOX	linezolid	FOR SUSPENSION;ORAL	021132-001	Apr 18, 2000	AB	RX	Yes	Yes
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-003	Apr 18, 2000	AP	RX	Yes	Yes
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-001	Apr 18, 2000	AP	RX	Yes	No
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-002	Apr 18, 2000		DISCN	Yes	No
Pfizer	ZYVOX	linezolid	TABLET;ORAL	021130-002	Apr 18, 2000		DISCN	Yes	No

International Patents for ZYVOX

See the table below for patents covering ZYVOX around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	717738
Poland	201686
South Africa	200207073	Oxazolidinone tablet formulation.
Argentina	027261	LINEZOLID FORMA CRISTALINA II
Austria	412413

Supplementary Protection Certificates for ZYVOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0717738	02C0005	France		PRODUCT NAME: LINEZOLIDE; NAT. REGISTRATION NO/DATE: NL 26 660 20010831; FIRST REGISTRATION: GB - PL 00 32/0261 20010105
0717738	CA 2002 00004	Denmark
0717738	SPC001/2002	Ireland		SPC001/2002: 20031204, EXPIRES: 20160104
0717738	PA2004004,C0717738	Lithuania		PRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313
0717738	PA2004004	Lithuania		PRODUCTNAME: LINEZOLIDUM - (S)-N-[[3-FLUOR-4-(4-MORFOLINIL)FENIL]-2-OKSO-5-OKSAZOLIDINIL]METIL]-ACETAMIDAS

ZYVOX (linezolid): Investment scenario and fundamentals analysis

Last updated: April 24, 2026

What is ZYVOX and what does it sell for?

ZYVOX is the brand name for linezolid, an oral and IV oxazolidinone antibiotic used for serious Gram-positive infections. The commercial product line is built around oral tablets/suspension and IV infusion formulations.

Core commercial profile

• Drug class: Oxazolidinone antibiotic
• MOA: Inhibits bacterial protein synthesis by binding the 50S ribosomal subunit
• Therapeutic focus: Serious Gram-positive infections including MRSA and VRE in approved indications (indication set varies by jurisdiction and labeling history)
• Form factors: Oral (tablets/suspension) and IV (infusion)

What matters for investment

• Linezolid pricing and volume track hospital antibiotic utilization and formulary placement more than retail demand.
• Cash flow is sensitive to generic substitution once patent exclusivity ends.
• The brand value for investors is primarily a function of gross margin durability, switching inertia (where hospital systems keep branded agents), and contracting strength.

How is the ZYVOX patent and exclusivity stack structured?

ZYVOX is a mature branded antibiotic. The key investment question is whether any remaining exclusivity or new patent estates protect meaningful brand economics, or whether the product is in a post-exclusivity generic-dominated phase.

Patent-exclusivity framework (US)

• Linezolid’s foundational patents and approvals date to the early 2000s.
• In the US, a branded antibiotic’s economic lifeline depends on:
  • Composition-of-matter and method patent coverage (expiry drives generic entry),
  • Orphan or pediatric exclusivity (if applicable),
  • Orange Book listings for branded formulations (especially IV vs oral) and any later-life patent grants tied to specific product changes.

For ZYVOX, the commercial reality for investors is that the linezolid molecule and the major formulations are no longer under long-term brand exclusivity in many markets, and value is increasingly driven by formulation-level rights and contracting rather than long-run molecule protection.

What do the fundamentals say about demand durability for linezolid?

Fundamental demand drivers

• Hospital inpatient flows: Linezolid use is concentrated in inpatient settings for serious Gram-positive infections.
• Resistance patterns: MRSA and VRE prevalence supports linezolid relevance even as prescribing guidance evolves.
• Clinical differentiation vs alternatives: Linezolid faces substitution by newer agents and older generics depending on:
  • local antibiogram trends,
  • formulary restrictions,
  • safety and monitoring requirements.

Key demand constraints

• Stewardship and guidance: Antibiotic stewardship policies increasingly restrict broad-spectrum agents unless criteria are met.
• Safety monitoring cost: Linezolid has known safety considerations (e.g., duration-related risks and drug interaction management), which can cap usage days.
• Generic price pressure: Generic availability typically compresses branded revenue unless contracts lock in branded supply or pricing.

What is the market competitive structure and why does it matter?

Linezolid’s competitive landscape in most developed markets is characterized by:

• Multiple generic manufacturers for core oral and IV presentations.
• Branded share retention driven by:
  • procurement preferences,
  • supply reliability,
  • hospital formulary placement,
  • reimbursement and contracting structures.

Investment implication

• The “brand” and the “API” economic outcomes diverge:
  • Branded holders can still earn meaningful cash flow when contracting preserves share at attractive net pricing.
  • If share shifts fully to generics, value becomes largely a commodity spread problem, not a premium brand equity story.

How does safety profile translate into prescribing and utilization behavior?

Linezolid’s safety and administration requirements influence utilization intensity and duration.

Safety-relevant factors affecting fundamentals

• Duration dependence: risk profiles can rise with longer treatment courses.
• Drug interactions: interaction management affects adoption in polypharmacy settings.
• Monitoring requirements: hospitals manage linezolid with protocol-driven monitoring, which can limit throughput and cap usage when monitoring resources are constrained.

These mechanics do not remove demand, but they can:

• constrain the number of eligible patients,
• reduce average treatment days,
• push clinicians toward alternatives for lower acuity cases.

What does pricing pressure mean for an investor in ZYVOX?

Price compression is the dominant near- to mid-cycle risk for ZYVOX-like legacy antibiotics. The primary economic levers are:

• net price after rebates and contracting,
• acquisition costs for branded inventory vs generic reference dynamics,
• supply chain stability,
• share retention in institutional formularies.

Investment read-through

• Without demonstrable incremental protection (new patents or meaningful formulation exclusivity), ZYVOX is typically a share-and-net-price story, not a growth story.
• Upside tends to come from:
  • institutional contract renewals,
  • product lifecycle defense (e.g., maintenance of IV or suspension supply contracts),
  • out-of-formulary exceptions that preserve usage share.

Investment scenario framework for ZYVOX

Base case: Branded share erosion continues

• Ongoing generic competition limits brand growth.
• Revenue becomes a function of maintaining net pricing and defending a stable hospital share.

Bull case: Contracting and supply defense stabilize net revenue

• Branded net pricing remains higher than generic equivalents due to:
  • substitution friction,
  • procurement preference for consistent supply,
  • clinical protocol inertia.
• Any new formulation-related rights or restricted substitution arrangements slow the share decline.

Bear case: Full generic conversion plus stewardship caps volume

• Rapid conversion to lowest net-cost generic linezolid.
• Stewardship policies reduce eligible usage days.
• Margin compresses as branded share falls and discounts deepen.

Key metrics to track (actionable diligence checklist)

1. US hospital channel share for oral and IV presentations (separate if reported).
2. Net price and rebate trend versus generic benchmark spreads.
3. Volume per patient-day proxies in inpatient antibiogram-relevant segments.
4. Contract duration and renewal terms for ID/hospital formularies.
5. Product-specific utilization: IV infusion share vs oral tablets, since contracting can preserve one channel longer than another.
6. Safety protocol adherence and monitoring-related policy changes that affect average treatment days.
7. Patent and Orange Book changes: new listings, litigation outcomes, or discontinuations that shift competitive dynamics.

What could change the investment profile in the next cycle?

For linezolid brands, the investment profile shifts when any of the following occurs:

• Regulatory labeling updates that change eligible use (expanding or tightening indications),
• New patent grants tied to specific formulations, manufacturing processes, or new dosing regimens,
• Litigation settlements that delay generic entry for a defined product presentation,
• Formulary policy changes that alter stewardship pathways,
• Supply constraints that temporarily raise branded leverage.

How ZYVOX should be valued from a fundamentals lens

Value logic

• Legacy antibiotics are valued on:
  • remaining branded cash flow after generic conversion,
  • net price durability under hospital contracting,
  • margin stability and inventory turn economics,
  • the expected rate of share decay.

Investor stance

• Treat ZYVOX as a mature franchise where:
  • long-run growth is limited,
  • outcomes hinge on defensive economics (net price, share retention) and legal/regulatory friction delaying generic replacement.

Key Takeaways

• ZYVOX is linezolid, a mature hospital antibiotic with demand anchored to serious Gram-positive infection treatment and resistance patterns (MRSA/VRE).
• Generic competition is the dominant economic force; investment returns depend on net price durability and institutional share defense, not molecule-level innovation.
• Fundamentals should be evaluated as a contracting and share-decay problem: separate oral vs IV channel performance, track rebate and net price trajectory, and monitor any Orange Book/patent events.
• Safety and stewardship policies influence eligible patient volume and average treatment days, affecting utilization more than headline incidence.

FAQs

1) Is ZYVOX still a growth product?
No. As a mature linezolid brand, ZYVOX is typically a cash-flow durability and share-defense investment rather than a high-growth story.

2) What drives ZYVOX demand most?
Inpatient hospital demand driven by serious Gram-positive infections, with utilization influenced by MRSA/VRE prevalence and stewardship protocols.

3) What is the biggest downside risk for ZYVOX investors?
Rapid shift to low-net-cost generic linezolid that compresses branded net pricing and erodes hospital share.

4) Does the oral vs IV split matter for valuation?
Yes. Hospital contracting can preserve one channel longer than the other, and the economic trajectory can diverge by presentation.

5) What diligence indicators predict branded durability?
Net price versus generic benchmarks, institutional contract renewal timing, and channel-specific volume stability (oral vs IV), alongside monitoring of any Orange Book or patent-litigation updates.

---

References

[1] Pfizer. ZYVOX (linezolid) prescribing information. (Accessed via FDA label repository).
[2] U.S. Food and Drug Administration. Approved drug products and prescribing information for ZYVOX (linezolid).